Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with a path to over $6B in revenue in FY26 despite maturing launches in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Near term, Wells thinks shares can trade up 15% in its base case for Vyvgart’s myositis Phase 3 expected in Q3 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $1,222 from $1,227 at Stifel
- Argenx Posts 63% Q1 Sales Surge as New CEO Steers Expansion of Autoimmune Portfolio
- Argenx Maintains Buy Rating on Vyvgart Momentum, Robust Profitability, and Expanding Late-Stage Pipeline
- Argenx Installs New CEO Karen Massey as Van Hauwermeiren Becomes Chair After AGM Approvals
- Argenx Completes First Safety Study for New Antibody ARGX-213